Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.

Cao L, Weetall M, Trotta C, Cintron K, Ma J, Kim MJ, Furia B, Romfo C, Graci JD, Li W, Du J, Sheedy J, Hedrick J, Risher N, Yeh S, Qi H, Arasu T, Hwang S, Lennox W, Kong R, Petruska J, Moon YC, Babiak J, Davis TW, Jacobson A, Almstead NG, Branstrom A, Colacino JM, Peltz SW.

Mol Cancer Ther. 2019 Jan;18(1):3-16. doi: 10.1158/1535-7163.MCT-18-0863. Epub 2018 Oct 23.

PMID:
30352802
2.

Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform.

Cao L, Weetall M, Bombard J, Qi H, Arasu T, Lennox W, Hedrick J, Sheedy J, Risher N, Brooks PC, Trifillis P, Trotta C, Moon YC, Babiak J, Almstead NG, Colacino JM, Davis TW, Peltz SW.

PLoS One. 2016 Dec 16;11(12):e0168366. doi: 10.1371/journal.pone.0168366. eCollection 2016.

3.

6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B.

Chen G, Ren H, Zhang N, Lennox W, Turpoff A, Paget S, Li C, Almstead N, Njoroge FG, Gu Z, Graci J, Jung SP, Colacino J, Lahser F, Zhao X, Weetall M, Nomeir A, Karp GM.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):781-6. doi: 10.1016/j.bmcl.2014.12.093. Epub 2015 Jan 7.

PMID:
25613678
4.

Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.

Zhang N, Zhang X, Zhu J, Turpoff A, Chen G, Morrill C, Huang S, Lennox W, Kakarla R, Liu R, Li C, Ren H, Almstead N, Venkatraman S, Njoroge FG, Gu Z, Clausen V, Graci J, Jung SP, Zheng Y, Colacino JM, Lahser F, Sheedy J, Mollin A, Weetall M, Nomeir A, Karp GM.

J Med Chem. 2014 Mar 13;57(5):2121-35. doi: 10.1021/jm401621g. Epub 2013 Dec 4.

PMID:
24266880
5.

Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.

Zhang X, Zhang N, Chen G, Turpoff A, Ren H, Takasugi J, Morrill C, Zhu J, Li C, Lennox W, Paget S, Liu Y, Almstead N, Njoroge FG, Gu Z, Komatsu T, Clausen V, Espiritu C, Graci J, Colacino J, Lahser F, Risher N, Weetall M, Nomeir A, Karp GM.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3947-53. doi: 10.1016/j.bmcl.2013.04.049. Epub 2013 Apr 30.

PMID:
23683597
6.

Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.

Cole DC, Stock JR, Lennox WJ, Bernotas RC, Ellingboe JW, Boikess S, Coupet J, Smith DL, Leung L, Zhang GM, Feng X, Kelly MF, Galante R, Huang P, Dawson LA, Marquis K, Rosenzweig-Lipson S, Beyer CE, Schechter LE.

J Med Chem. 2007 Nov 15;50(23):5535-8. Epub 2007 Oct 19.

PMID:
17948978
7.

Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists.

Cole DC, Lennox WJ, Stock JR, Ellingboe JW, Mazandarani H, Smith DL, Zhang G, Tawa GJ, Schechter LE.

Bioorg Med Chem Lett. 2005 Nov 1;15(21):4780-5.

PMID:
16125933
8.

Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists.

Cole DC, Lennox WJ, Lombardi S, Ellingboe JW, Bernotas RC, Tawa GJ, Mazandarani H, Smith DL, Zhang G, Coupet J, Schechter LE.

J Med Chem. 2005 Jan 27;48(2):353-6.

PMID:
15658848
9.

N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists.

Cole DC, Ellingboe JW, Lennox WJ, Mazandarani H, Smith DL, Stock JR, Zhang G, Zhou P, Schechter LE.

Bioorg Med Chem Lett. 2005 Jan 17;15(2):379-83.

PMID:
15603958
10.

Epilepsy: a paroxysmal cerebral dysrhythmia.

Gibbs FA, Gibbs EL, Lennox WG.

Epilepsy Behav. 2002 Aug;3(4):395-401. No abstract available.

PMID:
12609340
11.

Antagonism of soman-induced convulsions by midazolam, diazepam and scopolamine.

Anderson DR, Harris LW, Chang FC, Baze WB, Capacio BR, Byers SL, Lennox WJ.

Drug Chem Toxicol. 1997 Aug;20(3):115-31.

PMID:
9292273
12.

Efficacy comparison of scopolamine and diazepam against soman-induced debilitation in guinea pigs.

Anderson DR, Gennings C, Carter WH, Harris LW, Lennox WJ, Bowersox SL, Solana RP.

Fundam Appl Toxicol. 1994 May;22(4):588-93.

PMID:
8056205
13.

Efficacy comparison of scopolamine (SCP) and diazepam (DZ) against soman-induced lethality in guinea pigs.

Harris LW, Gennings C, Carter WH, Anderson DR, Lennox WJ, Bowersox SL, Solana RP.

Drug Chem Toxicol. 1994;17(1):35-50.

PMID:
8168432
14.

Efficacy of injectable anticholinergic drugs against soman-induced convulsive/subconvulsive activity.

Anderson DR, Harris LW, Bowersox SL, Lennox WJ, Anders JC.

Drug Chem Toxicol. 1994;17(2):139-48.

PMID:
8062641
15.

Reduction by pyridostigmine pretreatment of the efficacy of atropine and 2-PAM treatment of sarin and VX poisoning in rodents.

Koplovitz I, Harris LW, Anderson DR, Lennox WJ, Stewart JR.

Fundam Appl Toxicol. 1992 Jan;18(1):102-6.

PMID:
1601200
16.

Acetylcholinesterase inhibition and anti-soman efficacy of homologs of physostigmine.

Harris LW, Anderson DR, Pastelak AM, Bowersox SL, Vanderpool BA, Lennox WJ.

Drug Chem Toxicol. 1992;15(2):127-43.

PMID:
1597127
17.

The effect of pyridostigmine pretreatment on oxime efficacy against intoxication by soman or VX in rats.

Anderson DR, Harris LW, Woodard CL, Lennox WJ.

Drug Chem Toxicol. 1992;15(4):285-94.

PMID:
1459041
18.

Successful pretreatment/therapy of soman, sarin and VX intoxication.

Lennox WJ, Harris LW, Anderson DR, Solana RP, Murrow ML, Wade JV.

Drug Chem Toxicol. 1992;15(4):271-83.

PMID:
1459040
19.

Use of the accelerating rotarod for assessment of motor performance decrement induced by potential anticonvulsant compounds in nerve agent poisoning.

Capacio BR, Harris LW, Anderson DR, Lennox WJ, Gales V, Dawson JS.

Drug Chem Toxicol. 1992;15(3):177-201.

PMID:
1425360
20.

Evaluation of phosphinates as potential pretreatments for nerve agents.

Anderson DR, Harris LW, Lieske CN, Lennox WJ.

Life Sci. 1991;48(25):2463-8.

PMID:
2046471
21.

Physostigmine (alone and together with adjunct) pretreatment against soman, sarin, tabun and VX intoxication.

Harris LW, Talbot BG, Lennox WJ, Anderson DR, Solana RP.

Drug Chem Toxicol. 1991;14(3):265-81.

PMID:
1935706
22.

Effects of subacute pretreatment with carbamate together with acute adjunct pretreatment against nerve agent exposure.

Anderson DR, Harris LW, Lennox WJ, Solana RP.

Drug Chem Toxicol. 1991;14(1-2):1-19.

PMID:
1889370
23.

Evaluation of several oximes as reactivators of unaged soman-inhibited whole blood acetylcholinesterase in rabbits.

Harris LW, Anderson DR, Lennox WJ, Woodard CL, Pastelak AM, Vanderpool BA.

Biochem Pharmacol. 1990 Dec 15;40(12):2677-82.

PMID:
2260991
24.

Evaluation of the efficacy of two carbamates, physostigmine and pyridostigmine, when used in conjunction for protection against organophosphate exposure.

Solana RP, Gennings C, Carter WH Jr, Anderson D, Lennox WJ, Carchman RA, Harris LW.

Fundam Appl Toxicol. 1990 Nov;15(4):814-9.

PMID:
2086320
25.

Estimation of the LCt50 of phosgene in sheep.

Keeler JR, Hurt HH, Nold JB, Lennox WJ.

Drug Chem Toxicol. 1990;13(2-3):229-39.

PMID:
2276341
26.

Distal tibiofibular synostosis due to direct trauma.

Harborne DJ, Lennox WM.

Injury. 1989 Nov;20(6):377-8. No abstract available.

PMID:
2628342
27.

The relationship between oxime-induced reactivation of carbamylated acetylcholinesterase and antidotal efficacy against carbamate intoxication.

Harris LW, Talbot BG, Lennox WJ, Anderson DR.

Toxicol Appl Pharmacol. 1989 Mar 15;98(1):128-33.

PMID:
2494778
28.

Effects of subacute administration of physostigmine on blood acetylcholinesterase activity, motor performance, and soman intoxication.

Harris LW, Anderson DR, Lennox WJ, Solana RP.

Toxicol Appl Pharmacol. 1989 Feb;97(2):267-71.

PMID:
2922758
29.

A comparison of in vivo and in vitro rates of aging of soman-inhibited erythrocyte acetylcholinesterase in different animal species.

Talbot BG, Anderson DR, Harris LW, Yarbrough LW, Lennox WJ.

Drug Chem Toxicol. 1988;11(3):289-305.

PMID:
3181042
30.

Oxime-induced decarbamylation and atropine/oxime therapy of guinea pigs intoxicated with pyridostigmine.

Harris LW, Talbot BG, Anderson DR, Lennox WJ, Green MD.

Life Sci. 1987 Feb 9;40(6):577-83.

PMID:
3807651
31.

Relationship between reversible acetylcholinesterase inhibition and efficacy against soman lethality.

Lennox WJ, Harris LW, Talbot BG, Anderson DR.

Life Sci. 1985 Sep 2;37(9):793-8.

PMID:
4033355
32.

Protection against both lethal and behavioral effects of soman.

Harris LW, McDonough JH Jr, Stitcher DL, Lennox WJ.

Drug Chem Toxicol. 1984;7(6):605-24.

PMID:
6534735
33.

Toxicity of anticholinesterases: interactions of pyridostigmine and physostigmine with soman.

Harris LW, Lennox WJ, Talbot BG, Anderson DR, Swanson DR.

Drug Chem Toxicol. 1984;7(5):507-26.

PMID:
6510256
34.
35.

Synthesis and biological activity of new 2-substituted analogs of fluphenazine.

Bossle PC, Ferguson CP, Sultan WE, Lennox WJ, Dudley GE, Rea TH, Miller JI.

J Med Chem. 1976 Mar;19(3):370-3. No abstract available.

PMID:
943545
36.

Severe pseudomembranous colitis after lincomycin and clindamycin.

Smart RF, Ramsden DA, Gear MW, Nicol A, Lennox WM.

Br J Surg. 1976 Jan;63(1):25-9.

PMID:
1267870
37.

Three cases of intussusception of the small intestine in the dog.

Pass MA, Lennox WJ.

Can Vet J. 1972 Nov;13(11):266-9. No abstract available.

38.

Canine leishmaniasis in Canada.

Lennox WJ, Smart ME, Little PB.

Can Vet J. 1972 Aug;13(8):188-90. No abstract available.

39.

Thallium poisoning.

Lennox WJ.

Can Vet J. 1966 May;7(5):113-6. No abstract available.

40.

Physiotherapy and foot drop corrections.

Lennox WM.

Lepr Rev. 1966 Apr;37(2):99-102. No abstract available.

PMID:
4286510
41.

Plastic surgery of the anaesthetic foot of leprosy.

Lennox WM.

Lepr Rev. 1965 Jul;36(3):109-17. No abstract available.

PMID:
5871239
42.

THE SURGICAL MANAGEMENT OF FOOT DEFORMITIES IN LEPROSY.

LENNOX WM.

Lepr Rev. 1965 Jan;36:27-34. No abstract available.

PMID:
14241916
43.

A CLASSIFICATION OF LEPROSY FOOT DEFORMITIES.

LENNOX WM.

Lepr Rev. 1964 Oct;35:245-9. No abstract available.

PMID:
14213607
44.

Vaginal Prolapse in a Bitch.

Alexander JE, Lennox WJ.

Can Vet J. 1961 Nov;2(11):428-30. No abstract available.

45.

Methsuximide in psychomotor and petit-mal seizures.

FRENCH EG, REY-BELLET J, LENNOX WG.

N Engl J Med. 1958 May 1;258(18):892-4. No abstract available.

PMID:
13541681
46.

The centenary of bromides.

LENNOX WG.

N Engl J Med. 1957 May 9;256(19):887-90. No abstract available.

PMID:
13451959
47.

Long-term effects of phensuximide (milontin).

LENNOX WG, REY-BELLET J.

AMA Arch Neurol Psychiatry. 1957 Jan;77(1):23-7. No abstract available.

PMID:
13381213
48.

Epilepsy and the epileptic; guest editorial.

LENNOX WG.

J Am Med Assoc. 1956 Sep 8;162(2):118-9. No abstract available.

PMID:
13357305
49.

The reign of the uterus.

LENNOX WG.

Epilepsia. 1955 Nov;4:91-8. No abstract available.

PMID:
13305554
50.

Cyclic vomiting as a form of epilepsy in children.

MILLICHAP JG, LOMBROSO CT, LENNOX WG.

Pediatrics. 1955 Jun;15(6):705-14. No abstract available.

PMID:
14384370

Supplemental Content

Loading ...
Support Center